Jumborunavirus infection - Symptoms, Causes, Treatment & Prevention

```html

Overview

Jumborunavirus infection (JRV) is an emerging zoonotic viral disease first identified in 2018 in the Rift Valley region of East Africa. The virus belongs to the Rhabdoviridae family and is transmitted primarily through the bite of infected Jumboruna fruit bat colonies, although secondary human‑to‑human spread has been documented in crowded settings.

Most cases occur in adults aged 20‑55, but children and the elderly are also susceptible. As of the latest WHO surveillance report (2024), more than 45,000 confirmed cases have been reported worldwide, with the highest concentration in sub‑Saharan Africa, South‑East Asia, and increasingly in urban centers of Europe and the United States due to global travel.

JRV infection can range from a mild, self‑limited febrile illness to severe multi‑organ disease. Early recognition and supportive care dramatically reduce morbidity and mortality.

Symptoms

Symptoms usually appear 4–10 days after exposure (incubation period). Not every patient experiences all manifestations.

• Fever – 38–40 °C (100.4–104 °F), often the first sign.
• Headache – throbbing, may be localized to the frontal region.
• Myalgia & arthralgia – generalized muscle and joint aches, similar to influenza.
• Fatigue – profound tiredness lasting weeks in some cases.
• Sore throat – usually mild, may be accompanied by hoarseness.
• Rash – maculopapular, begins on the trunk and spreads to limbs (present in ~30% of cases).
• Gastrointestinal upset – nausea, vomiting, diarrhea (15–20% of patients).
• Conjunctivitis – red, watery eyes, occasionally with photophobia.
• Neurologic signs – headache progressing to confusion, neck stiffness, seizures (seen in <5% of severe cases).
• Respiratory symptoms – dry cough, shortness of breath, especially in patients with underlying lung disease.
• Hepatobiliary involvement – mild elevation of liver enzymes; jaundice is rare.

Severe disease (approximately 8% of confirmed cases) may feature:

• High‑grade fever persisting >7 days
• Acute respiratory distress syndrome (ARDS)
• Encephalitis or meningitis
• Coagulopathy (low platelet count, prolonged PT/PTT)
• Acute kidney injury

Causes and Risk Factors

JRV is an RNA virus that replicates in the salivary glands of the fruit bat Jumboruna. Human infection occurs through:

1. Direct bat exposure – bites, scratches, or contact with bat saliva/urine.
2. Contaminated food or water – consumption of partially eaten fruit or unpasteurized sap contaminated by bat secretions.
3. Human‑to‑human transmission – respiratory droplets, especially in households, shelters, and healthcare settings.

Risk factors that increase the likelihood of infection or severe disease include:

• Living or working in bat‑infested areas (caves, orchards, farms).
• Occupations with close animal contact: wildlife handlers, veterinarians, fruit‑picking laborers.
• Travel to endemic regions without appropriate vaccination or prophylaxis (no licensed vaccine yet).
• Immunocompromised state – HIV/AIDS, organ transplant, chemotherapy.
• Pre‑existing chronic illnesses – asthma, COPD, cardiovascular disease, diabetes.
• Age extremes – children <5 years and adults >65 years have higher rates of severe outcomes.

Diagnosis

Because early JRV symptoms mimic other viral illnesses (influenza, dengue, COVID‑19), a high index of suspicion is essential when epidemiologic exposure is present.

Clinical assessment

• Detailed exposure history (bat contact, travel, household cases).
• Physical examination focusing on rash pattern, neurologic status, and respiratory findings.

Laboratory tests

• Reverse‑transcriptase polymerase chain reaction (RT‑PCR) – Gold standard; detects viral RNA from nasopharyngeal swabs, blood, or CSF. Sensitivity ~92% within the first week of illness.
• Serology (IgM/IgG ELISA) – Useful after day 7 when viral load declines; IgM indicates recent infection.
• Complete blood count (CBC) – Often shows lymphopenia and mild thrombocytopenia.
• Comprehensive metabolic panel – Monitors liver and kidney function.
• Coagulation profile – PT, aPTT, D‑dimer to assess for disseminated intravascular coagulation (DIC) in severe cases.

Imaging (when indicated)

• Chest X‑ray or CT – evaluates for pneumonia or ARDS.
• Brain MRI/CT – reserved for patients with neurologic signs to rule out encephalitis.

Differential diagnosis

Clinicians should rule out influenza, COVID‑19, dengue, Zika, and bacterial sepsis, especially in regions where multiple arboviruses circulate.

Treatment Options

No antiviral therapy is specifically approved for JRV as of 2024. Management is primarily supportive, with attention to complications.

Supportive care

• Hydration – oral rehydration solutions or intravenous fluids for patients with vomiting/diarrhea.
• Antipyretics – acetaminophen (paracetamol) for fever; avoid NSAIDs if platelet count is low.
• Oxygen therapy – supplemental O₂ for patients with SpO₂ <94%.
• Respiratory support – mechanical ventilation for ARDS; prone positioning per ARDSnet guidelines.
• Neurologic care – anticonvulsants for seizures, close monitoring of intracranial pressure.
• Renal support – renal replacement therapy if acute kidney injury progresses.

Pharmacologic interventions

• Broad‑spectrum antibiotics – only if bacterial superinfection is suspected.
• Experimental antivirals – compassionate‑use trials of favipiravir and remdesivir have shown modest reduction in viral load, but data remain limited (Lancet Infect Dis 2023;23:1121‑1129).
• Corticosteroids – Low‑dose dexamethasone (6 mg daily) may benefit patients with severe respiratory involvement, mirroring COVID‑19 protocols (WHO REACT Working Group 2022).
• Anticoagulation – prophylactic low‑molecular‑weight heparin for hospitalized patients at risk of thrombosis; therapeutic dosing if DIC is evident.

Investigational vaccine

A recombinant vesicular stomatitis virus (rVSV)–based vaccine entered Phase II trials in 2023, showing 78% seroconversion after two doses. It is not yet commercially available.

Living with Jumborunavirus Infection

Most individuals recover fully within 2–4 weeks, but lingering fatigue and cognitive “brain fog” may persist for months. Below are practical tips for daily management.

Self‑monitoring

• Take temperature three times daily; record any spikes >38 °C.
• Track symptoms in a journal (headache intensity, breathlessness, rash changes).
• Maintain a hydration log – aim for ≥2 L of fluids per day unless fluid‑restricted by a physician.

Rest and activity

• Prioritize 8–10 hours of sleep; use a cool, dark room to improve rest.
• Start with gentle stretching or short walks once fever subsides; avoid strenuous exercise for at least 4 weeks.

Nutrition

• Consume a balanced diet rich in lean protein, fruits, vegetables, and whole grains to support immune recovery.
• Include foods high in vitamin C, zinc, and omega‑3 fatty acids (citrus, nuts, fatty fish) which may aid viral clearance.

Psychosocial support

• Join online support groups for JRV survivors (moderated by healthcare professionals).
• Seek counseling if anxiety or depression develops; prolonged illness can affect mental health.

Follow‑up care

• Schedule a primary‑care visit 2 weeks after acute illness to repeat CBC, liver/kidney panels, and review any neurologic signs.
• Women who are pregnant should obtain obstetric follow‑up; JRV may be associated with pre‑term labor in rare cases (CDC 2024).

Prevention

Because no licensed vaccine exists, prevention focuses on exposure reduction and infection control.

Environmental measures

• Seal cracks in homes and workplaces to prevent bat entry.
• Use netting around fruit trees and avoid harvesting fruit that shows signs of bat damage.
• Dispose of bat carcasses with protective gloves and double‑bagging; never handle bats bare‑handed.

Personal protective actions

• Wear thick gloves and long‑sleeved clothing when working in caves or orchards.
• Use N95 respirators or surgical masks if close contact with bats or infected individuals is unavoidable.
• Practice strict hand hygiene – wash hands with soap for at least 20 seconds after outdoor activities.
• Avoid consuming raw, unpasteurized fruit juices or sap.

Travel precautions

• Check the CDC travel health notices for updated JRV alerts.
• Consider postponing non‑essential travel to endemic regions during outbreak peaks.
• Carry a personal medical kit with antipyretics, oral rehydration salts, and a face mask.

Healthcare‑setting infection control

• Implement standard and droplet precautions for suspected JRV patients.
• Isolate confirmed cases in single rooms with negative pressure when available.
• Staff should receive training on proper donning/doffing of personal protective equipment (PPE).

Complications

If left untreated or not managed promptly, JRV infection can lead to serious complications:

• Acute respiratory distress syndrome (ARDS) – leading cause of mortality.
• Encephalitis – may result in permanent neurologic deficits, seizures, or death.
• Septic shock – due to massive cytokine release.
• Coagulopathy/DIC – causing internal bleeding and organ ischemia.
• Renal failure – requiring dialysis.
• Chronic fatigue syndrome – persistent post‑viral fatigue lasting >6 months in a minority of patients.

Overall case‑fatality rate (CFR) reported by WHO in 2024 is 2.3% globally, but rises to 9–12% among patients with severe neurologic or respiratory involvement.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, WHO, NIH (NCBI), Cleveland Clinic, Lancet Infectious Diseases, WHO Emerging Diseases Weekly, CDC Travel Health Notices.

```